ImmunityBio vs Kiniksa Pharmaceuticals International

ImmunityBio (IBRX), health care, and Kiniksa Pharmaceuticals International (KNSA), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Kiniksa Pharmaceuticals International is worth $7.5B on the stock market and ImmunityBio $6.7B: Kiniksa Pharmaceuticals International is valued at 12% more. ImmunityBio's operating margin in its latest fiscal year was -226% and Kiniksa Pharmaceuticals International's 11.4%. Over the past year ImmunityBio's share price has moved +185% and Kiniksa Pharmaceuticals International's +128%.

Key facts

ImmunityBio market value
$6.7B
Kiniksa Pharmaceuticals International market value
$7.5B
Kiniksa Pharmaceuticals International P/E
72.1
ImmunityBio revenue
$113.3MFY to 2025-12-31
Kiniksa Pharmaceuticals International revenue
$677.6MFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

ImmunityBio vs Kiniksa Pharmaceuticals International: every measure side by side
Measure ImmunityBio Kiniksa Pharmaceuticals International
SectorHealth CareHealth Care
Country United States United Kingdom
Fiscal year ends2025-12-312025-12-31
Size
Market cap$6.7Blower$7.5Bhigher
Revenue$113.3Mlower$677.6Mhigher
Earnings-$351.4Mlower$59Mhigher
Employees684higher366lower
Total assets$501.9Mlower$763.6Mhigher
Valuation
P/E—72.1
P/S58.8higher11.0lower
P/B——
Dividend yield0.00%—
Profitability
Operating margin-226%lower11.4%higher
Balance sheet
Net assets-$500.5Mlower$567.6Mhigher
Total liabilities$1Bhigher$196Mlower
Total debt——
Cash on hand$88.3Mlower$165.6Mhigher
Price change
Today+4.68%higher+0.93%lower
1 year+185%higher+128%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

ImmunityBio only (0)

None of the tracked investors.

Kiniksa Pharmaceuticals International only (1)

Percentages are each holding's share of that investor's reported portfolio. · Who owns KNSA

Further comparisons

Learn

Questions and answers

Which is bigger, ImmunityBio or Kiniksa Pharmaceuticals International?

By market value, Kiniksa Pharmaceuticals International is the larger: $7.5B against $6.7B for ImmunityBio. By revenue in its latest fiscal year, Kiniksa Pharmaceuticals International is the larger: $677.6M against $113.3M for ImmunityBio.

Which has the higher operating margin?

Kiniksa Pharmaceuticals International: 11.4%, against -226% for ImmunityBio. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which superinvestors own both ImmunityBio and Kiniksa Pharmaceuticals International?

None of the tracked superinvestors holds both in their latest 13F filing. 0 hold ImmunityBio and 1 holds Kiniksa Pharmaceuticals International.

Cite this page

Funkfolio, “ImmunityBio vs Kiniksa Pharmaceuticals International”, data as of 18 November 2026. https://funkfolio.com/compare/ibrx-vs-knsa

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.